Loading…
Loading…
600200.SS (JiangSu WuZhong Pharmaceutical Development Co., Ltd.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 600200.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 600200.SS and 80,000+ other tickers.
See exactly how 600200.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 600200.SS and 80,000+ other tickers.
JiangSu WuZhong Pharmaceutical Development Co., Ltd., along with its affiliated entities, operates as a diversified Chinese enterprise with interests spanning the pharmaceutical, real estate, and chemical industries. The company is actively involved in the research, production, and sale of a broad spectrum of pharmaceutical products. These include medications targeting infections, digestive ailments, cardiovascular and cerebrovascular conditions, viral diseases, vitamin deficiencies, and hemostasis. Its pharmaceutical offerings also encompass immunomodulators, featuring biopharmaceuticals…
No recent news available.